Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease

S Verma, M Al‐Omran, LA Leiter… - Diabetes, Obesity …, 2022 - Wiley Online Library
Aim To evaluate the cardiovascular (CV) efficacy of liraglutide and semaglutide in patients
with type 2 diabetes (T2D) and peripheral artery disease (PAD). Materials and Methods …

Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort

M Mirani, G Favacchio, E Serone, G Lucisano… - Pharmacological …, 2018 - Elsevier
In the last years, due to new regulatory guidelines requiring a stringent documentation of
cardiovascular (CV) safety of novel drugs for type 2 diabetes, cardiovascular outcomes …

Cardiovascular outcomes of liraglutide in patients with type 2 diabetes: A systematic review and meta-analysis

CM Duan, TF Wan, Y Wang, QW Yang - Medicine, 2019 - journals.lww.com
Background: Liraglutide is a novel, long-acting glucagon-like peptide-1 (GLP-1) analogue
used to treat type 2 diabetes mellitus. However, the cardiovascular safety and benefits of …

Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease: results of the LEADER trial

S Verma, DL Bhatt, SC Bain, JB Buse, JFE Mann… - Circulation, 2018 - Am Heart Assoc
CORRESPONDENCE years), and more patients were male (68.8% versus 67.9%), were
current or previous smokers (67.1% versus 60.1%), had an estimated glomerular filtration …

Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analysis …

S Verma, NR Poulter, DL Bhatt, SC Bain, JB Buse… - Circulation, 2018 - Am Heart Assoc
Background: The glucagon-like peptide-1 analog liraglutide reduced cardiovascular events
and mortality in patients with type 2 diabetes mellitus in the LEADER trial (Liraglutide and …

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials

S Verma, SC Bain, T Monk Fries… - Diabetes, Obesity …, 2019 - Wiley Online Library
Cardiovascular risk reduction with liraglutide and semaglutide in patients with type 2
diabetes was demonstrated in the LEADER (ClinicalTrials. gov: NCT01179048) and …

Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 …

S Verma, DK McGuire, SC Bain… - Diabetes, Obesity …, 2020 - Wiley Online Library
Associations between body mass index (BMI) and the cardiovascular (CV) and kidney
efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in patients with type 2 …

Occurence of first and recurrent major adverse cardiovascular events with liraglutide treatment among patients with type 2 diabetes and high risk of cardiovascular …

S Verma, SC Bain, JB Buse, T Idorn… - JAMA …, 2019 - jamanetwork.com
Importance After the occurrence of nonfatal cardiovascular events, recurrent events are
highly likely. Most cardiovascular outcomes trials analyze first events only; extending …

[HTML][HTML] Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial

SP Marso, NR Poulter, SE Nissen, MA Nauck… - American heart …, 2013 - Elsevier
Background Diabetes is a multisystem disorder associated with a nearly twofold excess risk
for a broad range of adverse cardiovascular outcomes including coronary heart disease …

Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use …

S Verma, LA Leiter, CD Mazer, SC Bain, J Buse… - Circulation, 2018 - Am Heart Assoc
Higher baseline LDL-C was associated with greater risk of MACEs. The crude proportion of
patients experiencing MACEs was 11.7% in the LDL-C< 50 mg/dL group, 13.9% in the LDL …